Royal Bank of Canada
MACK

Royal Bank of Canada’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Royal Bank of Canada’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-435
Closed -$6K – 7813
2024
Q1 		$6K Sell
435
-3,053
-88% -$42.9K ﹤0.01% 6418
2023
Q4 		$47K Buy
3,488
+2,147
+160% +$27.1K ﹤0.01% 6029
2023
Q3 		$16K Buy
1,341
+86
+7% +$1.04K ﹤0.01% 6267
2023
Q2 		$15K Buy
1,255
+1,247
+15,588% +$15.6K ﹤0.01% 6342
2023
Q1 		$0 Hold
8
– – ﹤0.01% 7877
2022
Q4 		$0 Sell
8
-3,531
-100% -$29.1K ﹤0.01% 8224
2022
Q3 		$13K Buy
3,539
+31
+0.9% +$143 ﹤0.01% 6326
2022
Q2 		$21K Hold
3,508
– – ﹤0.01% 6103
2022
Q1 		$22K Sell
3,508
-9
-0.3% -$51 ﹤0.01% 6570
2021
Q4 		$14K Buy
3,517
+1,509
+75% +$6.55K ﹤0.01% 6960
2021
Q3 		$10K Hold
2,008
– – ﹤0.01% 6992
2021
Q2 		$13K Hold
2,008
– – ﹤0.01% 6791
2021
Q1 		$13K Buy
2,008
+1,952
+3,486% +$14K ﹤0.01% 6706
2020
Q4 		$0 Sell
56
-221
-80% -$1.09K ﹤0.01% 7541
2020
Q3 		$1K Sell
277
-42
-13% -$154 ﹤0.01% 6556
2020
Q2 		$1K Sell
319
-67
-17% -$229 ﹤0.01% 6571
2020
Q1 		$0 Buy
386
+162
+72% +$474 ﹤0.01% 7345
2019
Q4 		$0 Buy
224
+55
+33% +$220 ﹤0.01% 7408
2019
Q3 		$1K Sell
169
-28
-14% -$140 ﹤0.01% 6623
2019
Q2 		$1K Hold
197
– – ﹤0.01% 6805
2019
Q1 		$1K Hold
197
– – ﹤0.01% 6746
2018
Q4 		$1K Sell
197
-89,805
-100% -$311K ﹤0.01% 6674
2018
Q3 		$378K Sell
90,002
-2,444
-3% -$10.3K ﹤0.01% 4080
2018
Q2 		$357K Buy
92,446
+309
+0.3% +$2.05K ﹤0.01% 4049
2018
Q1 		$583K Buy
92,137
+2,207
+2% +$18.3K ﹤0.01% 3594
2017
Q4 		$725K Sell
89,930
-1,551
-2% -$14.5K ﹤0.01% 3498
2017
Q3 		$1.05M Buy
91,481
+1,514
+2% +$15.9K ﹤0.01% 3188
2017
Q2 		$877K Sell
89,967
-62
-0.1% -$1.27K ﹤0.01% 3208
2017
Q1 		$2.18M Sell
90,029
-1,198
-1% -$30K ﹤0.01% 2484
2016
Q4 		$2.93M Buy
91,227
+342
+0.4% +$14.6K ﹤0.01% 2295
2016
Q3 		$4.54M Sell
90,885
-1,686
-2% -$70K ﹤0.01% 1979
2016
Q2 		$3.92M Sell
92,571
-146
-0.2% -$7.95K ﹤0.01% 2049
2016
Q1 		$6.11M Buy
92,717
+9,556
+11% +$499K ﹤0.01% 1688
2015
Q4 		$5.17M Buy
83,161
+76,315
+1,115% +$5.37M ﹤0.01% 1849
2015
Q3 		$459K Sell
6,846
-1,047
-13% -$85.5K ﹤0.01% 3599
2015
Q2 		$767K Buy
7,893
+381
+5% +$36.3K ﹤0.01% 3164
2015
Q1 		$702K Sell
7,512
-11,782
-61% -$1M ﹤0.01% 3187
2014
Q4 		$1.72M Buy
19,294
+5,058
+36% +$368K ﹤0.01% 2457
2014
Q3 		$983K Buy
14,236
+1,335
+10% +$71.3K ﹤0.01% 2869
2014
Q2 		$740K Sell
12,901
-191
-1% -$9.7K ﹤0.01% 3076
2014
Q1 		$520K Buy
13,092
+12,825
+4,803% +$549K ﹤0.01% 3322
2013
Q4 		$11K Sell
267
-286
-52% -$8.29K ﹤0.01% 5431
2013
Q3 		$17K Buy
553
+292
+112% +$10.2K ﹤0.01% 5244
2013
Q2 		$13K Buy
+261
New +$11.4K ﹤0.01% 5192

Other funds holding MACK

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
RA
Rise Advisors Rochester, New York $355M AUM 20.51% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada's MACK Position: Q2 2024 in Review

Royal Bank of Canada sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2024, closing a stake of 435 shares — an estimated $6K sold.

Royal Bank of Canada first reported a position in MACK in Q2 2013 and held it in 44 quarters. The position peaked at $6.11M in Q1 2016. 12 funds tracked by Wall St. Rank hold MACK as of Q2 2024.

  • Royal Bank of Canada reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Royal Bank of Canada sold 435 Merrimack Pharmaceuticals, Inc. shares in Q2 2024, an estimated $6K.
  • Royal Bank of Canada first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 44 quarters.
  • Royal Bank of Canada's Merrimack Pharmaceuticals, Inc. position peaked at $6.11M in Q1 2016.
  • 12 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2024.

Based on Royal Bank of Canada's 13F filing for Q2 2024, filed 14 Aug 2024.